Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Venomtech was a UK biotechnology and discovery-tools company focused on using venom-derived compounds to support early-stage drug discovery, crop science, and cosmetic research. The company built and supplied targeted and diversity venom libraries, including its Targeted Venom Discovery Arrays (T-VDA™), along with custom array design, toxin purification, whole venom supply, and hit-to-lead support services. Its scientific value proposition centered on accessing bioactive peptides, proteins, and other venom components for hard-to-hit targets such as ion channels, GPCRs, kinases, and related mechanisms. Venomtech also promoted applications in pain, oncology, antimicrobial research, and skin-related cosmetic products. Although its website remains online, the registered UK entity Venomtech Limited is listed in liquidation, so it should be treated as inactive as a corporate operating entity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Venomtech.